Cowen and Company’s Trillium Therapeutics Inc. TRIL Stock Holding History

Cowen and Company’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-22,070	Closed	-$325K	–	705
2020 Q4	$325K	Buy	+22,070	New	+$318K	0.03%	139

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Cowen and Company's TRIL Position: Q1 2021 in Review

Cowen and Company sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 22,070 shares — an estimated $325K sold.

Cowen and Company first reported a position in TRIL in Q4 2020 and held it in 1 quarter. The position peaked at $325K in Q4 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

Cowen and Company reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
Cowen and Company sold 22,070 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $325K.
Cowen and Company first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 1 quarter.
Cowen and Company's Trillium Therapeutics Inc. position peaked at $325K in Q4 2020.
125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on Cowen and Company's 13F filing for Q1 2021, filed 4 May 2021.